目的:观察慢性心力衰竭急性失代偿期(ADHF)患者治疗前后血清乙酰肝素酶(HPSE)水平变化,研究慢性心力衰竭患者疗效与血清HPSE水平变化的相关性。方法: 选取住院的ADHF患者50名纳入心衰治疗组,同期住院的有基础心脏病但尚未达到心衰程度的30名患者作为试验对照组,以及同期体检的30名健康正常人纳入正常对照组。观察心衰治疗组治疗前后血清HPSE的变化及与N端脑钠肽前体(N terminal pro brain natriuretic peptide, NT-proBNP)的相关性。结果: 心衰治疗后较治疗前血HPSE和NT-proBNP水平均明显降低(P＜0.05);治疗前血清HPSE水平高于试验对照组及正常对照组;治疗后血清HPSE指标高于正常对照组(P＜0.05),与试验对照组无显著差异(P＞0.05)。Pearson相关分析提示治疗前后血HPSE和NT-proBNP水平呈正相关。结论: ADHF患者血清HPSE水平显著增高,纠正心衰后指标明显下降,且与血NT-proBNP水平呈正相关,血清HPSE水平可能与心衰严重程度有相关性。
Objective: To observe the changes of serum heparanase levels in patients with acute decompensated chronic heart failure before and after treatment, and to study the correlation between the efficacy and changes in serum HPSE levels in patients with chronic heart failure. Methods: Fifty hospitalized patients with ADHF were selected and included in the treatment group, 30 patients with underlying heart disease but not yet reaching the level of heart failure who were hospitalized during the same period served as the experimental control group, and 30 healthy individuals who underwent physical examination during the same period were included in the normal control group. The changes of serum HPSE in patients with heart failure before and after treatment were detected by ELISA, and the relationship between NT-proBNP and serum heparanase in the treatment group before and after treatment and in the control group was observed. Results: After heart failure treatment, the levels of HPSE and NT-proBNP were significantly lower than those before treatment, and the difference was statistically significant (P＜0.05). The level of serum HPSE before treatment was higher than that of the experimental and normal control groups, and the serum HPSE after treatment was higher than that of the normal control group. There was no significant difference with the experimental control group (P＞0.05). Pearson correlation analysis indicated that blood HPSE and NT-proBNP levels were positively correlated before and after treatment. Conclusion: Serum HPSE levels were significantly higher in patients with ADHF, and the index decreased significantly after correction of heart failure, and was positively correlated with NT-proBNP levels; serum HPSE levels may be correlated with the severity of heart failure.
[1] Arrigo M, Jessup M, Mullens W, et al. Acute heart failure[J].Nat Rev Dis Primers, 2020, 6(1): 16.
[2] Masola V, Bellin G, Gambaro G, et al. Heparanase: A multitasking protein involved in extracellular matrix (ECM) remodeling and intracellular events[J].Cells, 2018, 7(12): 236.
[3] Eustes AS, Campbell RA, Middleton EA, et al. Heparanase expression and activity are increased in platelets during clinical sepsis[J].J Thromb Haemost, 2021, 19(5): 1319-1330.
[4] Aldi S, Eriksson L, Kronqvist M, et al. Dual roles of heparanase in human carotid plaque calcification[J].Atherosclerosis, 2019, 283: 127-136.
[5] Yang XH, Dai RX, Qin Z, et al. LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention[J].Sci Rep, 2022, 12(1): 3294.
[6] Ghoti H, Ackerman S, Rivella S, et al. Heparanase level and procoagulant activity are increased in thalassemia and attenuated by Janus kinase 2 inhibition[J].Am J Pathol, 2020, 190(10): 2146-2154.
[7] Gembillo G, Siligato R, Amatruda M, et al. Vitamin D and glomerulonephritis[J].Medicina (Kaunas), 2021, 57(2): 186.
[8] Novick D, Barak S, Ilan N, et al. Heparanase interacts with resistin and augments its activity[J].PLoS One, 2014, 9(1): e85944.
[9] 王华, 梁延春. 中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志, 2018, 46(10): 760-789.
[10] Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure[J].Circ Res, 2021, 128(10): 1468-1486.
[11] McKie PM, Burnett JC Jr. NT-proBNP: the gold standard biomarker in heart failure[J].J Am Coll Cardiol, 2016, 68(22): 2437-2439.
[12] Koganti R, Suryawanshi R, Shukla D. Heparanase, cell signaling, and viral infections[J].Cell Mol Life Sci, 2020, 77(24): 5059-5077.
[13] ESC Scientific Document Group, McDonagh TA, Metra M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).With the special contribution of the Heart Failure Association (HFA) of the ESC[J].Eur J Heart Fail, 2022, 24(1): 4-131.
[14] Van den Hoven MJ, Waanders F, Rops AL, et al. Regulation of glomerular heparanase expression by aldosterone, angiotensin Ⅱ and reactive oxygen species[J].Nephrol Dial Transplant, 2009, 24(9): 2637-2645.
[15] Zechendorf E, Vaßen P, Zhang J, et al. Heparan sulfate induces necroptosis in murine cardiomyocytes: a medical-In silico approach combining In vitro experiments and machine learning[J].Front Immunol, 2018, 9: 393.
[16] Ishiguro-Oonuma T, Suemoto M, Okada M, et al. Aberrant gene expression of heparanase in ventricular hypertrophy induced by monocrotaline in rats[J].J Vet Med Sci, 2016, 78(3): 499-503.
[17] Shang R, Lal N, Puri K, et al. Involvement of heparanase in endothelial cell-cardiomyocyte crosstalk[J].Adv Exp Med Biol, 2020, 1221: 721-745.
[18] Lal N, Chiu AP, Wang F, et al. Loss of VEGFB and its signaling in the diabetic heart is associated with increased cell death signaling[J].Am J Physiol Heart Circ Physiol, 2017, 312(6): H1163-H1175.
[19] Psotka MA, Gottlieb SS, Francis GS, et al. Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week[J].J Am Coll Cardiol, 2019, 73(18): 2345-2353.
[20] Couchman JR, Multhaupt H, Sanderson RD. Recent insights into cell surface heparan sulphate proteoglycans and cancer[J].F1000Res, 2016, 5: F1000 Faculty Rev-1541.
[21] Garsen M, Lenoir O, Rops AL, et al. Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx[J].J Am Soc Nephrol, 2016, 27(12): 3545-3551.
[22] Mayfosh AJ, Nguyen TK, Hulett MD. The heparanase regulatory network in health and disease[J].Int J Mol Sci, 2021, 22(20): 11096.
[23] Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart[J].Peptides, 2019, 111: 18-25.
[24] Rørth R, Jhund PS, Yilmaz MB, et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction[J].Circ Heart Fail, 2020, 13(2): e006541.
[25] Zile MR, Claggett BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure[J].J Am Coll Cardiol, 2016, 68(22): 2425-2436.
